Trillium Asset Management LLC purchased a new stake in Five Prime Therapeutics Inc. (NASDAQ:FPRX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 62,445 shares of the company’s stock, valued at approximately $2,582,000.
A number of other hedge funds also recently bought and sold shares of the company. Legal & General Group Plc increased its position in Five Prime Therapeutics by 15.8% in the first quarter. Legal & General Group Plc now owns 3,869 shares of the company’s stock worth $160,000 after buying an additional 527 shares during the last quarter. Strs Ohio increased its position in Five Prime Therapeutics by 8.7% in the second quarter. Strs Ohio now owns 22,500 shares of the company’s stock worth $930,000 after buying an additional 1,800 shares during the last quarter. TIAA CREF Investment Management LLC increased its position in Five Prime Therapeutics by 1.3% in the first quarter. TIAA CREF Investment Management LLC now owns 141,867 shares of the company’s stock worth $5,764,000 after buying an additional 1,871 shares during the last quarter. Williams Jones & Associates LLC acquired a new position in Five Prime Therapeutics during the first quarter worth approximately $240,000. Finally, Meeder Asset Management Inc. acquired a new position in Five Prime Therapeutics during the second quarter worth approximately $268,000. Institutional investors own 86.49% of the company’s stock.
Shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) traded down 0.97% during trading on Friday, reaching $51.81. 260,649 shares of the company traded hands. The company has a 50-day moving average of $49.35 and a 200-day moving average of $45.51. Five Prime Therapeutics Inc. has a 12 month low of $15.27 and a 12 month high of $55.00. The stock has a market capitalization of $1.39 billion, a PE ratio of 5.83 and a beta of 4.46.
Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.07. Five Prime Therapeutics had a net margin of 63.88% and a return on equity of 69.59%. The firm had revenue of $9.23 million for the quarter, compared to the consensus estimate of $6.38 million. During the same period in the previous year, the company earned ($0.45) earnings per share. The company’s quarterly revenue was up 46.1% on a year-over-year basis. Analysts forecast that Five Prime Therapeutics Inc. will post ($2.37) earnings per share for the current fiscal year.
A number of equities analysts have recently commented on the stock. Leerink Swann reaffirmed an “outperform” rating and set a $58.00 price objective (up from $45.00) on shares of Five Prime Therapeutics in a report on Monday, August 8th. Jefferies Group set a $60.00 price objective on shares of Five Prime Therapeutics and gave the stock a “buy” rating in a report on Friday, August 5th. Finally, Credit Suisse Group AG reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a report on Tuesday, July 12th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $52.33.
In other Five Prime Therapeutics news, Director William R. Ringo sold 500 shares of the company’s stock in a transaction on Monday, August 1st. The shares were sold at an average price of $50.77, for a total value of $25,385.00. Following the transaction, the director now directly owns 500 shares in the company, valued at $25,385. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Peder Jensen sold 12,195 shares of the company’s stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $49.50, for a total transaction of $603,652.50. Following the completion of the transaction, the director now owns 12,195 shares in the company, valued at $603,652.50. The disclosure for this sale can be found here. 5.30% of the stock is currently owned by company insiders.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.